FR2873368B1 - Derives de guanidine et leurs utilisations en therapeutique - Google Patents

Derives de guanidine et leurs utilisations en therapeutique

Info

Publication number
FR2873368B1
FR2873368B1 FR0408237A FR0408237A FR2873368B1 FR 2873368 B1 FR2873368 B1 FR 2873368B1 FR 0408237 A FR0408237 A FR 0408237A FR 0408237 A FR0408237 A FR 0408237A FR 2873368 B1 FR2873368 B1 FR 2873368B1
Authority
FR
France
Prior art keywords
therapeutics
guanidine derivatives
guanidine
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0408237A
Other languages
English (en)
Other versions
FR2873368A1 (fr
Inventor
Didier Roche
Bruno Roux
Isabelle Berard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sante SAS
Original Assignee
Merck Sante SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0408237A priority Critical patent/FR2873368B1/fr
Application filed by Merck Sante SAS filed Critical Merck Sante SAS
Priority to PCT/EP2005/006929 priority patent/WO2006010422A1/fr
Priority to CA002574947A priority patent/CA2574947A1/fr
Priority to CNA2005800250453A priority patent/CN1989120A/zh
Priority to MX2007000856A priority patent/MX2007000856A/es
Priority to US11/572,663 priority patent/US7582656B2/en
Priority to EP05759228A priority patent/EP1771428A1/fr
Priority to RU2007106935/04A priority patent/RU2007106935A/ru
Priority to BRPI0513744-6A priority patent/BRPI0513744A/pt
Priority to AU2005266661A priority patent/AU2005266661A1/en
Priority to JP2007522936A priority patent/JP2008507571A/ja
Priority to KR1020077001872A priority patent/KR20070043804A/ko
Priority to ARP050103034A priority patent/AR050180A1/es
Publication of FR2873368A1 publication Critical patent/FR2873368A1/fr
Priority to ZA200701634A priority patent/ZA200701634B/en
Application granted granted Critical
Publication of FR2873368B1 publication Critical patent/FR2873368B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/18—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FR0408237A 2004-07-26 2004-07-26 Derives de guanidine et leurs utilisations en therapeutique Expired - Fee Related FR2873368B1 (fr)

Priority Applications (14)

Application Number Priority Date Filing Date Title
FR0408237A FR2873368B1 (fr) 2004-07-26 2004-07-26 Derives de guanidine et leurs utilisations en therapeutique
JP2007522936A JP2008507571A (ja) 2004-07-26 2005-06-28 グアニジン誘導体および治療でのその使用
CNA2005800250453A CN1989120A (zh) 2004-07-26 2005-06-28 胍衍生物和其治疗用途
MX2007000856A MX2007000856A (es) 2004-07-26 2005-06-28 Derivados de guanidina y sus usos terapeuticos.
US11/572,663 US7582656B2 (en) 2004-07-26 2005-06-28 Guanidine derivatives and therapeutic uses thereof
EP05759228A EP1771428A1 (fr) 2004-07-26 2005-06-28 Derives de la guanidine et utilisations therapeutiques de ceux-ci
RU2007106935/04A RU2007106935A (ru) 2004-07-26 2005-06-28 Производные гуанидина и их терапевтическое применение
BRPI0513744-6A BRPI0513744A (pt) 2004-07-26 2005-06-28 derivados de guanidina e usos terapêuticos dos mesmos
PCT/EP2005/006929 WO2006010422A1 (fr) 2004-07-26 2005-06-28 Derives de la guanidine et utilisations therapeutiques de ceux-ci
CA002574947A CA2574947A1 (fr) 2004-07-26 2005-06-28 Derives de la guanidine et utilisations therapeutiques de ceux-ci
KR1020077001872A KR20070043804A (ko) 2004-07-26 2005-06-28 구아니딘 유도체 및 이의 치료적 용도
AU2005266661A AU2005266661A1 (en) 2004-07-26 2005-06-28 Guanidine derivatives and therapeutic uses thereof
ARP050103034A AR050180A1 (es) 2004-07-26 2005-07-22 Derivados de guanidina y sus usos terapeuticos
ZA200701634A ZA200701634B (en) 2004-07-26 2007-02-23 Guanidine derivatives and therapeutic uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0408237A FR2873368B1 (fr) 2004-07-26 2004-07-26 Derives de guanidine et leurs utilisations en therapeutique

Publications (2)

Publication Number Publication Date
FR2873368A1 FR2873368A1 (fr) 2006-01-27
FR2873368B1 true FR2873368B1 (fr) 2008-01-04

Family

ID=34946751

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0408237A Expired - Fee Related FR2873368B1 (fr) 2004-07-26 2004-07-26 Derives de guanidine et leurs utilisations en therapeutique

Country Status (14)

Country Link
US (1) US7582656B2 (fr)
EP (1) EP1771428A1 (fr)
JP (1) JP2008507571A (fr)
KR (1) KR20070043804A (fr)
CN (1) CN1989120A (fr)
AR (1) AR050180A1 (fr)
AU (1) AU2005266661A1 (fr)
BR (1) BRPI0513744A (fr)
CA (1) CA2574947A1 (fr)
FR (1) FR2873368B1 (fr)
MX (1) MX2007000856A (fr)
RU (1) RU2007106935A (fr)
WO (1) WO2006010422A1 (fr)
ZA (1) ZA200701634B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2009108280A (ru) 2006-08-08 2010-09-20 Санофи-Авентис (Fr) Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011157827A1 (fr) 2010-06-18 2011-12-22 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683699B1 (fr) 2011-03-08 2015-06-24 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120057A1 (fr) 2011-03-08 2012-09-13 Sanofi Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation
WO2012120054A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
EP2567959B1 (fr) 2011-09-12 2014-04-16 Sanofi Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2014015157A2 (fr) 2012-07-19 2014-01-23 Philadelphia Health & Education Corporation Nouveaux ligands du récepteur sigma et procédés de modulation de l'homéostase de protéine cellulaire à l'aide de ceux-ci
EP3018125B1 (fr) 2013-07-03 2020-08-05 Shin Nippon Biomedical Laboratories, Ltd. Nouveau composé, agent de détection du transporteur de cations organiques 3 et inhibiteur de l'activité du transporteur de cations organiques 3
WO2019089902A1 (fr) 2017-11-01 2019-05-09 Drexel University Composés, compositions et méthodes pour traiter des maladies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19610932A1 (de) * 1996-03-20 1997-09-25 Bayer Ag 2-Aryl-substituierte Pyridine
ITRM20020625A1 (it) 2002-12-17 2004-06-18 Sigma Tau Ind Farmaceuti Derivati di guanidine variamente sostituite, loro uso come medicamenti ad attivita' antidiabetica e/o antiobesita'.
ZA200508439B (en) * 2003-05-05 2007-03-28 Probiodrug Ag Medical use of inhibitors of glutaminyl and glutamate cyclases

Also Published As

Publication number Publication date
RU2007106935A (ru) 2008-09-10
AU2005266661A1 (en) 2006-02-02
BRPI0513744A (pt) 2008-05-13
ZA200701634B (en) 2008-07-30
JP2008507571A (ja) 2008-03-13
EP1771428A1 (fr) 2007-04-11
US7582656B2 (en) 2009-09-01
FR2873368A1 (fr) 2006-01-27
AR050180A1 (es) 2006-10-04
MX2007000856A (es) 2007-03-12
KR20070043804A (ko) 2007-04-25
US20080004315A1 (en) 2008-01-03
CA2574947A1 (fr) 2006-02-02
CN1989120A (zh) 2007-06-27
WO2006010422A1 (fr) 2006-02-02

Similar Documents

Publication Publication Date Title
FR2873368B1 (fr) Derives de guanidine et leurs utilisations en therapeutique
FR2883000B1 (fr) Derives de trifluoromethylbenzamide et leurs utilisations en therapeutique
CR8037A (es) Derivados de 2- acilamino- 4- feniletiazol, su preparacion y su aplicacion en terapeutica
NO2017002I1 (no) Cobicistat eller farmasøytisk akseptabelt salt derav og atazanavir eller farmasøytisk akseptabelt salt derav, spesielt atazanavirsulfat
CY2017006I2 (el) Αερολυμενες φθοροκινολονες και χρησεις αυτων
AP2006003820A0 (en) Piperazin derivatives and their use in controllingpests
DK3401327T3 (da) Genprodukter med forskellig ekspression i tumorer og anvendelser deraf
NO20055017D0 (no) Tradlose sensorer i valsebelegg
IL185034A0 (en) 1,5-diarylpyrrole derivatives, preparation method thereof and application of same in therapeutics
DK2517750T3 (da) Foldet kateteraggregat med klæbegreb og fremgangsmåde til fremstilling deraf
PT1419150E (pt) Derivados de 1-fenilsulfonil-1,3-di-hidro-2h-indol-2-ona, sua preparacao e sua aplicacao em terapeutica
NO20055122D0 (no) Klesplagg og lommefestesystem
DE60238980D1 (de) Verbesserungen in Funkortungsystemen
IS8575A (is) 3-ß-D-ríbófúranósýlþíasóló [4,5-d]pýridímínnúkleósíð og notkun þeirra
PT1513836E (pt) Derivados de piperazinilacilpiperidina, sua preparacao e sua aplicacao em terapeutica
DE602004003162D1 (de) Verbesserungen in oder in Bezug auf dynamischer Bilderzeugung
NL1029139A1 (nl) Nieuwe aminopyridinederivaten en hun gebruik als farmaceutica.
FR2922209B1 (fr) 5,6-DIARYLES PYRIDINES SUBSTITUES EN POSITION 2 et 3, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE.
FR2866340B1 (fr) Derives d'oxazole, leur preparation et leur utilisation en therapeutique.
DK1615536T3 (da) Forbedringer i sanitære ruller
IL188032A0 (en) Derivatives of 4,5-diarylpyrrole, preparation method thereof and use of same in therapeutics
FR2903106B1 (fr) Utilisations de 2-benzoyl-imidazopyridines en therapeutique
FR2873118B1 (fr) Derives de pyrido-pyrimidine, leur application en therapeutique
MA28847B1 (fr) Derives de pyrrole, leur preparation et leur utilisation en therapeutique
IL195207A0 (en) Aryl-and heteroaryl-ethyl-acylguanidine derivatives, their preparation and their application in therapeutics

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20140331